Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Biohaven Pharmaceutical

Biohaven Pharmaceutical
2013 FOUNDED
PUBLIC STATUS
61-70 EMPLOYEES
BHVN STOCK SYMBOL
4 INVESTMENTS
$41.06 SHARE PRICE (As of Friday Closing)
Description

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. Its product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. The company's pipeline products include BHV3000-301, BHV3000-302, BHV3000-303 and others.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NYS
Primary Office
  • 234 Church Street
  • New Haven, CT 06510
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Biohaven Pharmaceutical’s full profile, request a free trial.

Biohaven Pharmaceutical Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$29.17 - $67.86 $1.83B $39.88 -$5.28 926K 44.5M

Biohaven Pharmaceutical Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 2,131,465 1,502,555 953,000
Revenue 0 0 0 0
EBITDA (198,706) (228,691) (125,278) (63,059)
Net Income (217,764) (240,922) (127,190) (63,677)
Total Assets 245,080 290,012 146,888 27,017
Total Debt 117,515 0 4,811
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biohaven Pharmaceutical Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Biohaven Pharmaceutical‘s full profile, request access.

Request full access to PitchBook

Biohaven Pharmaceutical Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ALSP Venture Capital-Backed San Diego, CA 00 00.000 00000 00000
000000000 00000000 Venture Capital-Backed Cambridge, MA 00 000.00 0&0
000000 00000000000 Failed Transaction (M&A) San Diego, CA 000 00000 000000&0
000000 (0000000000 Angel-Backed New York, NY 0 00000 0000000000 00000
000000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
To view this company’s complete list of competitors, request access »

Biohaven Pharmaceutical Investments (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 0000000000000 13-Nov-2018 00000 00000 00 0000 Biotechnology
0000000-00000 0000 02-Oct-2017 000000000 00000 00 Buildings and Property
0000 0000000000000 03-May-2017 00000 00000 00 000.00 Biotechnology 0000 00000 00
Fox Chase Chemical Diversity Center 01-Oct-2015 Grant 00.00 Biotechnology
To view this company’s complete investment and acquisition history, request access »

Biohaven Pharmaceutical Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Biohaven Pharmaceutical‘s full profile, request access.

Request full access to PitchBook

Biohaven Pharmaceutical Executive Team (14)

Name Title Board
Seat
Contact
Info
Vlad Coric MD Chief Executive Officer & Director
James Engelhart Chief Financial Officer
Robert Croop MD Chief Development Officer, Neurology
Charlie Conway Ph.D Chief Scientific Officer
Robert Berman MD Chief Medical Officer & Alternate Director

2 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Biohaven Pharmaceutical Board Members (9)

Name Representing Role Since Contact
Info
00000 00000 00.0 Fox Chase Chemical Diversity Center Board Member 000 0000
00000 00000 00.0 Biohaven Pharmaceutical Board Member 000 0000
0000 000000 00 Aisling Capital Board Member 000 0000

6 Former Board Members

You’re viewing 3 of 9 board members. Get the full list »